Pfizer collaborates with BioNTech to develop flu vaccines
Pfizer has entered into a multi-year collaboration with immunotherapy company BioNTech to develop messenger ribonucleic acid-based (mRNA) vaccines for influenza.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 October 2017 Pharmaceutical company Sanofi has announced it is investing €170 million ($202 million) to expand an influenza vaccine production facility in France.
12 October 2017 Pharmaceutical company Sanofi has announced it is investing €170 million ($202 million) to expand an influenza vaccine production facility in France.
12 October 2017 Pharmaceutical company Sanofi has announced it is investing €170 million ($202 million) to expand an influenza vaccine production facility in France.
